| 体内研究: |
FCPR03 (1.25-5 mg/kg;腹膜内注射;一次;成年雄性 Sprague-Dawley 大鼠) 处理可减少 MCAO 后大鼠的梗塞体积并改善神经行为结果。FCPR03 增加大鼠脑缺血再灌注后缺血半暗带磷酸化 AKT、GSK3β 和 β-catenin 的水平。 |
| 参考文献: |
1. Bingtian Xu, et al. FCPR03, a Novel Phosphodiesterase 4 Inhibitor, Alleviates Cerebral ischemia/reperfusion Injury Through Activation of the AKT/GSK3β/ β-catenin Signaling Pathway. Biochem Pharmacol. 2019 May;163:234-249. 2. Zheng-Qiang Zou, et al. Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF- κ B Inhibition. J Pharmacol Exp Ther. 2017 Jul;362(1):67-77. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.341 ml |
16.705 ml |
33.41 ml |
| 5 mM |
0.668 ml |
3.341 ml |
6.682 ml |
| 10 mM |
0.334 ml |
1.671 ml |
3.341 ml |
| 50 mM |
0.067 ml |
0.334 ml |
0.668 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |